CL2022002136A1 - Moduladores de la monoacilglicerol lipasa. - Google Patents

Moduladores de la monoacilglicerol lipasa.

Info

Publication number
CL2022002136A1
CL2022002136A1 CL2022002136A CL2022002136A CL2022002136A1 CL 2022002136 A1 CL2022002136 A1 CL 2022002136A1 CL 2022002136 A CL2022002136 A CL 2022002136A CL 2022002136 A CL2022002136 A CL 2022002136A CL 2022002136 A1 CL2022002136 A1 CL 2022002136A1
Authority
CL
Chile
Prior art keywords
methods
disorders
modulators
monoacylglycerol lipase
depression
Prior art date
Application number
CL2022002136A
Other languages
English (en)
Inventor
Brian Ngo Laforteza
Michael K Ameriks
Cynthia B Berry
Pablo Garcia-Reynaga
Jimmy T Liang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2022002136A1 publication Critical patent/CL2022002136A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de azabiciclo 3.1.0 y 4.1.0 de la Fórmula (I), composiciones farmacéuticas que los contienen, métodos para elaborarlos, y métodos para usarlos que incluyen métodos para tratar estados de enfermedad, trastornos, y afecciones asociados con la modulación de la MGL, tales como aquellos asociados con el dolor, los trastornos psiquiátricos, los trastornos neurológicos (incluidos, pero que no se limitan a, el trastorno depresivo mayor, la depresión resistente al tratamiento, la depresión ansiosa, el trastorno bipolar), los cánceres y las afecciones oculares. ; en donde X, Y, R1 , R2a y R2b se definen en la presente descripción
CL2022002136A 2020-02-10 2022-08-08 Moduladores de la monoacilglicerol lipasa. CL2022002136A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062972484P 2020-02-10 2020-02-10

Publications (1)

Publication Number Publication Date
CL2022002136A1 true CL2022002136A1 (es) 2023-02-03

Family

ID=74595268

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002136A CL2022002136A1 (es) 2020-02-10 2022-08-08 Moduladores de la monoacilglicerol lipasa.

Country Status (21)

Country Link
US (2) US11708359B2 (es)
EP (1) EP4103557A1 (es)
JP (1) JP2023512729A (es)
KR (1) KR20220140581A (es)
CN (1) CN115066422A (es)
AR (1) AR121296A1 (es)
AU (1) AU2021220539A1 (es)
BR (1) BR112022015116A2 (es)
CA (1) CA3169988A1 (es)
CL (1) CL2022002136A1 (es)
CO (1) CO2022011275A2 (es)
CR (1) CR20220376A (es)
DO (1) DOP2022000162A (es)
EC (1) ECSP22062460A (es)
IL (1) IL295447A (es)
JO (1) JOP20220180A1 (es)
MX (1) MX2022009804A (es)
PE (1) PE20221576A1 (es)
TW (1) TW202140465A (es)
UY (1) UY39066A (es)
WO (1) WO2021160602A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022015116A2 (pt) 2020-02-10 2022-09-27 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipase
BR112022019155A2 (pt) 2020-03-26 2022-12-06 Janssen Pharmaceutica Nv Aril piperidinas como moduladores da monoacilglicerol lipase
CN115335365B (zh) 2020-03-26 2024-06-18 詹森药业有限公司 氨基环丁烷作为单酰基甘油脂肪酶调节剂
AU2021241888A1 (en) 2020-03-26 2022-09-29 Janssen Pharmaceutica Nv Azaspirocycles as monoacylglycerol lipase modulators
CN118076351A (zh) 2021-08-09 2024-05-24 詹森药业有限公司 用于自闭症谱系障碍的单酰基甘油脂肪酶调节剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
KR20140068243A (ko) * 2011-09-30 2014-06-05 얀센 파마슈티카 엔.브이. 대사 질환 및 관련 장애의 치료를 위한 모노아실글리세롤 리파제 억제제
EP3438109B1 (en) 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
MY194647A (en) * 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
EP3689879A4 (en) 2017-09-29 2021-07-14 Takeda Pharmaceutical Company Limited HETEROCYCLIC CONNECTION
WO2020211798A1 (zh) 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
BR112022015116A2 (pt) * 2020-02-10 2022-09-27 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipase
BR112022019155A2 (pt) 2020-03-26 2022-12-06 Janssen Pharmaceutica Nv Aril piperidinas como moduladores da monoacilglicerol lipase
CN115335365B (zh) 2020-03-26 2024-06-18 詹森药业有限公司 氨基环丁烷作为单酰基甘油脂肪酶调节剂
AU2021241888A1 (en) 2020-03-26 2022-09-29 Janssen Pharmaceutica Nv Azaspirocycles as monoacylglycerol lipase modulators

Also Published As

Publication number Publication date
EP4103557A1 (en) 2022-12-21
DOP2022000162A (es) 2022-10-31
CN115066422A (zh) 2022-09-16
US11708359B2 (en) 2023-07-25
KR20220140581A (ko) 2022-10-18
US20210253565A1 (en) 2021-08-19
AU2021220539A1 (en) 2022-10-06
US20230382902A1 (en) 2023-11-30
CA3169988A1 (en) 2021-08-19
WO2021160602A1 (en) 2021-08-19
CO2022011275A2 (es) 2022-08-30
BR112022015116A2 (pt) 2022-09-27
ECSP22062460A (es) 2022-11-30
JOP20220180A1 (ar) 2023-01-30
CR20220376A (es) 2022-09-16
IL295447A (en) 2022-10-01
MX2022009804A (es) 2022-09-02
UY39066A (es) 2021-08-31
AR121296A1 (es) 2022-05-04
JP2023512729A (ja) 2023-03-28
TW202140465A (zh) 2021-11-01
PE20221576A1 (es) 2022-10-06

Similar Documents

Publication Publication Date Title
CL2022002136A1 (es) Moduladores de la monoacilglicerol lipasa.
NI202100023A (es) Moduladores de monoacilglicerol lipasa
MX2021003661A (es) Moduladores de la monoacilglicerol lipasa.
Géléoc et al. Sound strategies for hearing restoration
MX2022011904A (es) Aminociclobutanos como moduladores de monoacilglicerol lipasa.
MX2022011903A (es) Azaspirociclos como moduladores de monoacilglicerol lipasa.
BR112022019155A2 (pt) Aril piperidinas como moduladores da monoacilglicerol lipase
BR112022019077A2 (pt) Moduladores da monoacilglicerol lipase
Adatia et al. Proprioceptive innervation of the tongue.
PE20220901A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
AR038483A1 (es) Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides
CL2023001195A1 (es) Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades.
PE20212196A1 (es) Compuestos, composiciones, y metodos para modular la actividad cdk9
EA201992127A1 (ru) ФАРМАКОЛОГИЧЕСКИ АКТИВНЫЕ АЛИЦИКЛИЧЕСКИ ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА
UY38304A (es) Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen
PE20230106A1 (es) Compuestos de pirimidina fusionados como moduladores de kcc2
CO2024001524A2 (es) Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos
BR112023001060A2 (pt) Composto, composição farmacêutica, combinação, processo para fabricar uma composição farmacêutica, e, método de tratamento e/ou prevenção de um transtorno
El-Hashash Neural crest stem cells: a therapeutic hope machine for neural regeneration
CO2023003078A2 (es) Compuestos como moduladores de bis-fosfoglicerato mutasa para el tratamiento de la anemia de células falciforme
AR127356A1 (es) Moduladores de micromoléculas de la actividad de la glucocerebrosidasa y usos de estos
CO2024002084A2 (es) Compuestos n-acilidrazónicos inhibidores de nav 1.7 y/o nav 1.8, sus procesos de obtención, composiciones, usos, métodos de tratamiento de estos y kits
AR124316A1 (es) Compuestos para tratar una enfermedad respiratoria
Марянян et al. Cell technologies in regenerative medicine
Li et al. Biological characteristics and clinical application of skin-derived precursor cells